Biologic treatment system and method
AssigneeAMS Research Corporation
InventorThomas Q. Dinh
Life of this patent
Estimating the term…
Abstract
A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent, The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.
Claims25
A biologic delivery system for treating pelvic disorders in a patient, comprising:
- a biologic that is a particularized non-chemically crosslinked porcine dermis loaded with a bioactive agent selected from the group consisting of a growth factor and a hormone, the bioactive agent releasable at a target tissue within a pelvic region of a patient;
- and
- a device adapted to deliver the loaded bioactive agent to the target tissue within the pelvic region of the patient.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A biologic delivery system for treating pelvic disorders in a patient, comprising:
- a particularized biologic that is a particularized non-chemically crosslinked porcine dermis loaded with a bioactive agent adapted to promote pelvic tissue strengthening, such that the biologic is degradable over time to release the bioactive agent;
- and
- a needle device adapted to deliver the biologic into target tissue within the pelvic region of the patient.
(canceled)
(canceled)
(canceled)
A method of treating a pelvic disorder in a patient with a biologic delivery device, comprising:
- providing a particularized biologic that is a particularized non-chemically crosslinked porcine dermis loaded with a bioactive agent selected from the group consisting of a growth factor and a hormone adapted to promote pelvic tissue strengthening, such that the biologic is degradable over time to release the bioactive agent;
- providing a needle device adapted to hold and deliver the particularized biologic;
- and
- injecting the particularized biologic into target tissue within the pelvic region of the patient.
(canceled)
Dependencies are inferred from the claim text.